% | $
Quotes you view appear here for quick access.


  • tony_montello2003 tony_montello2003 Nov 13, 2013 2:08 PM Flag


    IMO, it would be very hard to find a more potentially explosive stock at this time and at this price. With patience, HOLDING and adding along the way is the formula for future reward. Buying now early in trials, to me, is worth the gamble. Could this NOT be successfull? Sure there is always that possibility, but all investments are met with risk/reward. But the reward of an outcome of successfull trials will lead to unprecedented news coverage and euphoria in the medical arena, public opinion and WALL STREET. For that day I will wait. Try and time the market? Not for me.--- And remember, if this trial is given the green light by the FDA, it WILL validate the success potential of future trils for ACTC's other uses for various forms of stem cells. The future use of stem cells for presently incurable medical conditions would be mind boggling. The market potential just for the ACTC RPE cell therapy to treat Advanced Macular Degeneration and SMD will be north of 50 Billion dollars and the market cap is measly 160 million. This is indeed the biggest opportunity in history of wall street!
    Let it be written,
    Dr. Tony Montello is here 2.7 million shares holding Long and Strong.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Time has come to start the music my puppets, at last a victory for those who suffer from AMD/SMD!
      The Good Doctor just left the building.)
      DR. Tony Montello

      Sentiment: Strong Buy

    • Tony, ever think of changing your id to FOB(Full Of Bull)?

    • Folks, The sec settlement PR as early as Monday, Lincoln Park capital selling more shares to pay for the 3 million dollar plus settlement. ACTC pps will have a knee jerk reaction than blast off to stratosphere with FDA news.
      Let it be written,
      Dr. Tony Montello

      Sentiment: Strong Buy

    • FDA to grant ACTC RPE CELL THERAPY breakthrough therapy designation:
      Many people with serious or life-threatening illnesses for which there are no satisfactory treatments are understandably eager to gain access to new therapies and are willing to trade off greater certainty about a drug's performance for speed of access. Because the typical clinical drug-development program takes about 7 years, during which a substantial body of safety and efficacy data is generated, the Food and Drug Administration (FDA) has long-standing expedited pathways available for drugs being studied for such illnesses. However, many patients and their advocates continue to believe that clinical development is sometimes prolonged beyond what is necessary. During the congressional considerations leading up to passage of the FDA Safety and Innovation Act of 2012 (FDASIA), a variety of provisions related to this theme were put on the table. When the bill was enacted, two modifications of the Federal Food, Drug, and Cosmetic Act addressed the issue of drug development for serious illnesses: a new “breakthrough therapy” designation for investigational drugs and expansion of the statute regarding accelerated approval. The breakthrough-therapy designation has since been introduced into the FDA portfolio of expedited programs for serious conditions.

      Some of these targeted therapies achieve a much larger treatment effect than currently available therapies — effects that are obvious even in the initial trials in humans. It is possible that manufacturing will become the rate-limiting step in some breakthrough-therapy drug-development.
      Let it be written,
      Dr. Tony Montello just left the building.)

      Sentiment: Strong Buy

    • ACTC is 3 years away Tony !! Stop the pumping lies !! It takes at least 10 years to complete all phases .. so far ? We are almost there but not yet !! Be patient , like me , and all we be fine !

    • The only reason that people still own stock is because of the stellar science and its potential but that can change in a heart beat if GR decides to dilute with billions more stock and the r/s. The stock then will go to a penny and Gary will make money from the fallout but hardly anyone else. That is how this could not be successful.

      Sentiment: Hold

    • It would be hard to find a potentially more disastrous stock. 99% losses here since ipo. My hubby became a hobo after losing his bum here.

    • Doc,
      Excellent post, welcome back. I agree those here that think they can touch Actc under .45 when phase 1 top line interim results are released are kidding themselves ..

      Sentiment: Strong Buy

    • "IMO, it would be very hard to find a more potentially explosive stock at this time and at this price."

      Yeah, I love the way it's exploding from 6 cents down toward 5 cents. And I especially love that Gary's salary over the past 3 months is more than 6 times greater than the current 3rd quarter revenues.
      Only in America does a CEO lose 322% of his shareholder value, yet recieve a raise for it, a raise that pushes his annual salry above $1M.

    • I agree with you. I think we will be hearing multiple news shortly...just a hunch.

    • View More Messages